FDA approval

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

FDA approval
Dec 19, 2024, 17:09 | Blog
Lisa A. Lacasse: Urgent call to pass the MCED Act for multi-cancer detection
Lisa A. Lacasse, President of the American Cancer Society Cancer Action Network (ACS CAN), shared…
Dec 5, 2024, 22:48 | Blog
Enrique Grande: FGFR inhibitors shaping the future of precision medicine
Enrique Grande, the Head of Oncology at MD Anderson Cancer Center Madrid, posted the following on…
Nov 17, 2024, 07:43 | Blog
Tanja Obradovic: Important milestone for Dizal Pharmaceutical with sunvozertinib NDA submission
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on LinkedIn:…
Nov 15, 2024, 15:14 | Blog
Brian Shields: AstraZeneca withdraws Lung Cancer Application for TROP2 - directed ADC
Brian Shields, Creator of KOL Pulse AI, shared a post on LinkedIn: "PR professionals in Pharma…
Nov 3, 2024, 11:54 | Dialogues
Zolbetuximab: From Promising Drug to FDA Approval | Exclusive Interview with Astellas
In this episode of OncoDaily, Dr. Moitreyee Chatterjee-Kishore and Tomoko Nakajima from Astellas Pharma join…
Oct 25, 2024, 13:37 | Blog
Bringing the Promise of Immunotherapy to More Patients - Cancer Research Institute
Cancer Research Institute shared a post on LinkedIn: "The Cancer Research Institute’s investment in research is…
Sep 28, 2024, 07:02 | Blog
Rahul Gosain: Osimertinib now FDA approved after LAURA Phase III study
Rahul Gosain shared the following on LinkedIn: “Osimertinib now FDA approved based off LAURA: Ph III,…
Sep 19, 2024, 11:55 | Insight
Aakash Desai: Efficacy, Innovation and Cost of FDA-Approved NSCLC Drugs
Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn: “We're excited to…
Sep 2, 2024, 10:54 | Opinion
David Fajgenbaum: It's a common misconception that approval marks the peak of a drug's journey
David Fajgenbaum shared on X: “When a drug receives FDA approval, its research and development…
Aug 27, 2024, 21:34 | Insight
Shahrin Ahmed: Addressing weaknesses in invasive brain cancer by utilizing ROBO1 CAR T cells
Shahrin Ahmed, Medical Specialist at the Canadian Cancer Society, shared a post on X: “Exploiting…
Aug 20, 2024, 10:11 | Blog
Jarushka Naidoo: Third neoadjuvant FDA approval in NSCLC
Jarushka Naidoo posted on X: "Third neoadjuvant FDA approval in NSCLC, now for perioperative durvalumab, based…
Aug 5, 2024, 04:49 | Drugs
Maria Babak: Key highlight from The Babak Lab on FDA Approval for Adagrasib
Maria Babak shared a post by The Babak Lab on LinkedIn: "This FDA approval represents…
Aug 4, 2024, 18:55 | Drugs
Amol Akhade: First T cell therapy for metastatic synovial sarcoma
Amol Akhade shared a post on X: "FDA approves first T cell therapy for metastatic…
Jul 9, 2024, 15:37 | Insight
10 Most Promising Cancer Drugs in 2024: What Patients Need to Know
Navigating the world of cancer treatment can be overwhelming, especially with so many new drugs…
Jul 7, 2024, 14:59 | Insight
Advancements in Oncology and Cancer Understanding - The Babak Lab
The Babak Lab made the following post on LinkedIn: "Weekly Digest Advancements in Oncology and Cancer…
Jul 1, 2024, 13:53 | Drugs
Todd Davis: Approval of Verona Pharma’s Ohtuvayre
Todd Davis, CEO at Ligand Pharmaceuticals, shared on LinkedIn: "When I stepped in as CEO…
Jun 26, 2024, 14:10 | Blog
Maria Babak: Rapid Progress in Metastatic Urothelial Carcinoma
Maria Babak shared a post by The Babak Lab on LinkedIn: “The FDA's approval of…
Jun 22, 2024, 15:13 | Drugs
Vivek Subbiah: Another FDA approval to adagrasib plus cetuximab for KRAS G12C-mutated colorectal cancer
Vivek Subbiah shared on LinkedIn: "It's Friday and time for another FDA approval! FDA grants…
Jun 16, 2024, 05:49 | Drugs
Vivek Subbiah: Another Tissue-Agnostic FDA approval
Vivek Subbiah shared on LinkedIn:                  . "Yes!…
Jun 15, 2024, 14:10 | Drugs
Vivek Subbiah: FDA granted full traditional approval of RET inhibitor Selpercatinib in RET+ thyroid cancers
Vivek Subbiah shared on LinkedIn:             . "FDA granted full traditional…
May 24, 2024, 01:21 | Insight
Recent FDA Committee Vote Could Speed Multiple Myeloma Drug Approval
Sylvester-led analysis on minimal residual disease as clinical endpoint guided committee decision A U.S. Food…
May 20, 2024, 14:16 | Blog
PR Yu: Stephen Towe, CEO of Leo Cancer Care, shared the exciting news of receiving 510k approval from the FDA
PR Yu, Founder and Managing Partner of Yu Galaxy, shared on LinkedIn: "I was elated…
May 20, 2024, 13:49 | Opinion
Amy Moore: BIG DEAL for those living with small cell lung cancer
Amy Moore, VP of Global Engagement and Patient Partnerships, LUNGevity Foundation, shared a post by LUNGevity…
May 18, 2024, 02:46 | Drugs
Vivek Subbiah: US FDA granted accelerated approval to tarlatamab-dlle
Vivek Subbiah shared on X: "New FDA Approval. Today the US FDA granted accelerated approval…
Apr 29, 2024, 07:58 | Blog
Rahul Gosain: FDA approval of Fruquintinib from FRESCO2 and how it fits in our Rx paradigm with N. Arvind Dasari
Rahul Gosain, Co-Founder of Oncology Brothers podcast and Director of Regional Infusion Services and Medical…
Apr 26, 2024, 10:07 | Drugs
Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer
Rami Manochakian, Associate Professor and Thoracic Oncologist at Mayo Clinic, shared on X/Twitter: ''HOT OFF…
Apr 24, 2024, 09:13 | Drugs
FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
FDA, the Food and Drug Administration, approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC) with…
Mar 28, 2024, 03:11 | Drugs
Yüksel Ürün: US FDA approves mirvetuximab soravtansine-gynx for FRα+ platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer
Yüksel Ürün, Professor of Medical Oncology at Ankara University School of Medicine, shared a post…
Mar 5, 2024, 19:49 | Insight
Eric K. Singhi: Great to see this option approved for our patients with Exon 20 Group insertions
Eric K. Singhi, Thoracic Medical Oncologist and Assistant Professor at the MD Anderson Cancer Center,…
Feb 25, 2024, 15:31 | Opinion
Aaron Goodman: Until a trial demonstrates melflufen is superior to melphalan I see no reason to use it
Aaron Goodman shared a post on X: "Chemo is bad and toxic! Attach a peptide…
Jan 22, 2024, 14:19 | Blog
Vivek Subbiah: 'Was great to partner with her and the team on the Selpercatinib RET fusion tissue agnostic approval
Vivek Subbiah recently shared on X/Twitter: "So nice to catch up with the terrific Dr.…
Dec 30, 2023, 04:09 | Drugs
Spencer Knight: Here’s the current 34 approval breakdown by therapeutic area
Spencer Knight, Senior Business Consultant of Cell and Gene Therapy at Charlton Morris, shared on…
Dec 27, 2023, 14:02 | Drugs
Vivek Subbiah: The FDA just finalized the draft guidance for 'RARE DISEASE DRUG DEVELOPMENT'
Vivek Subbiah recently shared on LinkedIn: "Wow! The FDA just finalized the draft guidance for…
Dec 8, 2023, 17:50 | Drugs
Pure Biologics to test molecule PBA-0405 in project PB004 in a Phase 0 clinical trial in patients with solid tumors - The Antibody Society
The Antibody Society shared on their LinkedIn page: "In an unusual (to us anyway) move,…
Dec 5, 2023, 12:57 | Drugs
Toby Eyre: Big news in CLL
Toby Eyre, CLL specialist at Oxford University Hospitals, announced on X/Twitter: "Big news in CLL.…
Nov 28, 2023, 16:43 | Drugs
Vivek Subbiah: Pleased to share our review on RET inhibitors
Vivek Subbiah shared on LinkedIn: "Pleased to share our review on RET inhibitors and RET inhibitor…
Aug 11, 2023, 19:30 | Drugs
Vivek Subbiah: Pralsetinib has received FULL FDA approval
Exciting News for RET+ patients! Pralsetinib has received FULL FDA approval! From treating the 1st…
All: 37 Posts: 1 - 100
Special Coverage